John Hunter Hospital

Running trials

• Not yet recruiting

  Validation Of anatomY-specific Aortic Valve Implantation Guided by Software Using EncantoR

  NCT07696182· Abbott Medical Devices· Source

• Recruiting

  Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy

  NCT07606352· Phase 2· Sitala Bio LTD· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Enrolling by invitation

  An Extension of SKY-0515 in Participants With Huntington's Disease

  NCT07537075· Phase 2/3· Skyhawk Therapeutics, Inc.· Source

• Recruiting

  AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

  NCT07194382· Phase 2· Avalyn Pharma Inc.· Source

• Recruiting

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

  NCT07332481· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

  NCT07282574· Phase 2· Hoffmann-La Roche· Source

• Not yet recruiting

  Multicomponent Breathlessness and Physical Activity Intervention in People With Asthma Using a Digital Platform

  NCT07421115· University of Newcastle, Australia· Source

• Recruiting

  A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

  NCT07361302· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  PRIORITY-CONNECT 2 Trial

  NCT06976710· Surgical Outcomes Research Centre (SOuRCe)· Source

• Recruiting

  Safety, Tolerability and Efficacy of Adjunctive TBO-309 in Reperfusion for Stroke With Tandem Occlusion

  NCT06813651· Phase 2· ThromBio Pty. Ltd.· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

  NCT06782490· Phase 2· Celgene· Source

• Active, not recruiting

  Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

  NCT06735534· Boston Scientific Corporation· Source

• Active, not recruiting

  Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease

  NCT06873334· Phase 2/3· Skyhawk Therapeutics, Inc.· Source

• Recruiting

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06935357· Phase 3· Biogen· Source

• Recruiting

  An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

  NCT06951217· Phase 2· Avalyn Pharma Inc.· Source

• Recruiting

  Implementing Surgery School Prehabilitation Using Telehealth

  NCT06631872· University of Melbourne· Source

• Recruiting

  The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

  NCT06058585· Phase 3· The George Institute· Source

• Active, not recruiting

  Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06564142· Phase 3· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source

• Not yet recruiting

  Australasian Nanoparticle-mediated Magnetically Enhanced Diffusion for Ischemic Stroke

  NCT06495671· University of Melbourne· Source

• Recruiting

  Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)

  NCT06226805· Phase 2· Basking Biosciences, Inc.· Source

• Recruiting

  Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

  NCT06218875· W.L.Gore & Associates· Source

• Active, not recruiting

  A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

  NCT06329401· Phase 2· Avalyn Pharma Inc.· Source

• Active, not recruiting

  A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

  NCT06200207· Phase 3· Novo Nordisk A/S· Source

• Enrolling by invitation

  ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

  NCT05932615· Abbott Medical Devices· Source

• Recruiting

  AusCADASIL: An Australian Cohort of CADASIL

  NCT06148051· Perminder Sachdev· Source

• Recruiting

  Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke

  NCT05363397· Phase 2· The Florey Institute of Neuroscience and Mental Health· Source

• Active, not recruiting

  Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System

  NCT05501873· Boston Scientific Corporation· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  RESPONDER-HF Trial

  NCT05425459· Corvia Medical· Source

• Active, not recruiting

  The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

  NCT05374291· Phase 3· University Medical Center Groningen· Source

• Active, not recruiting

  Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

  NCT05248646· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Recruiting

  Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke

  NCT05105633· Phase 2/3· University of Melbourne· Source

• Recruiting

  A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.

  NCT03998319· Phase 3· University of Sydney· Source

• Active, not recruiting

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

  NCT07218029· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Ultra-Early, Minimally inVAsive intraCerebral Haemorrhage evacUATion Versus Standard trEatment

  NCT04434807· University of Melbourne· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

  NCT04544449· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia

  NCT05524077· Western Sydney Local Health District· Source

• Recruiting

  The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study

  NCT04204915· University of Leicester· Source

• Recruiting

  Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress

  NCT03968393· Phase 4· Population Health Research Institute· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

  NCT03900429· Phase 3· Madrigal Pharmaceuticals, Inc.· Source

• Recruiting

  The EXCEL Registry of Patients Requiring ECMO

  NCT03793257· Australian and New Zealand Intensive Care Research Centre· Source

• Active, not recruiting

  Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients

  NCT02922036· EBR Systems, Inc.· Source

• Active, not recruiting

  REDUCE LAP-HFREF TRIAL

  NCT03093961· Corvia Medical· Source

• Recruiting

  Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)

  NCT03588286· Western Sydney Local Health District· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Stroke8 recruiting
• Aortic stenosis3 recruiting
• Coronary artery disease2 recruiting
• Crohn's disease2 recruiting
• Heart failure2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• IgA nephropathy2 recruiting
• Multiple sclerosis2 recruiting
• Aortic aneurysm1 recruiting
• Asthma1 recruiting
• Atrial fibrillation1 recruiting
• Chronic kidney disease1 recruiting
• Colorectal cancer1 recruiting
• High blood pressure1 recruiting
• Huntington's disease1 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

  NCT06926660· Phase 2· Boehringer Ingelheim· Source

• Completed

  Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

  NCT06153693· Phase 3· Mineralys Therapeutics Inc.· Source

• Completed

  SUBLOCADE Long-term Outcomes

  NCT05860959· Indivior Inc.· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  Post Market Clinical Follow-up Study for the Pamira ICD Lead Family

  NCT05621187· Biotronik SE & Co. KG· Source

• Completed

  BIO|CONCEPT.Amvia Study

  NCT05610176· Biotronik Australia Pty Ltd.· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

• Completed

  A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

  NCT04896008· Phase 3· Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA· Source

• Completed

  A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

  NCT04732221· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Completed

  Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

  NCT04435626· Phase 3· Bayer· Source

• Terminated

  Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients with Large Vessel Occlusion

  NCT04454788· Phase 3· University of Melbourne· Source

• Completed

  Optimize PRO Study

  NCT04091048· Medtronic Cardiovascular· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

• Completed

  Cardiac Magnetic Resonance GUIDEd Management of Mild-moderate Left Ventricular Systolic Dysfunction.

  NCT01918215· Flinders University· Source

• Completed

  A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion

  NCT02398656· Phase 3· University of Calgary· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Multiple sclerosis35 works · 3 trials
• Irritable bowel syndrome5 works · 0 trials
• IgA nephropathy4 works · 4 trials
• ANCA-associated vasculitis4 works · 0 trials